A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
← catalyst calendarNCT07284849 · readout in 863 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
700estimated
Sites
254
Countries
Argentina, Australia, Austria +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-05 | actual | When the study began enrolling |
| Primary completion | 2028-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CRC (Colorectal Cancer)
Interventions
- Drug: INCA33890
- Drug: Placebo
- Drug: Bevacizumab
- Drug: FOLFOX
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Up to 3 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed